跳至主要内容
临床试验/JPRN-jRCTs051180042
JPRN-jRCTs051180042招募中2 期

Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomas - GD therapy for advanced sarcomas

Hara Hitomi0 个研究点目标入组 20 人开始时间: 2019年1月30日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 10age old 至 <= 70age 11month 4weeks old(—)
性别
All

入选标准

  • 1)Patients are histopathologically diagnosed as the primary malignant tumor (sarcoma) of bone and soft tissue.
  • 2)Patients with advanced bone and soft tissue sarcoma having recurrence or metastasis.
  • 3)Patients who have previously received a standard therapy for bone and soft tissue sarcoma or could not receive a standard therapy.
  • 4)Patients who aged 10 to 70 years old at the time of enrollment.
  • 5)Patients who have a measurable evaluation lesion.
  • 6)Performance status (PS) is 0 or 1 in a standard of ECOG.
  • 7)Patients who have a primary tumor that appeared in extremity or trunk.
  • 8)Laboratory data within 14 days prior to enrollment meet all of the followings:
  • 1.Neutrophil more than 1,500 /mm3
  • 2.Hemoglobin more than 8.0 g/dL (there is no blood transfusion within 14 days)
  • 3.Platelet more than 100,000/mm3
  • 4.Total bilirubin less than 1.5 mg/dL
  • 5.AST(GOT) less than 100IU/L
  • 6.ALT(GPT) less than 100IU/L
  • 7.Creatinine less than 1.5 mg/dL
  • 8.Creatinine clearance (eGFR) more than 60 mL/min
  • 9)normal electrocardiogram within 28 days prior to enrollment
  • 10)Patients without interstitial pneumonia, pulmonary fibrosis, pulmonary emphysema.
  • 11)Patients were given a written explanation of the study protocol and provided their written informed consent.

排除标准

  • 1)Active double cancers within 5 years(cured intraepithelial carcinoma and intramucosal carcinoma are not included)
  • 2)Cases with complications of severe infection
  • 3) Patients who have hypersensitivity to study drugs
  • 4) Patients who have hypersensitivity to polysorbate 80
  • 5) Body temperature more than 38 degree
  • 6) Pregnant or breastfeeding women
  • 7) Severe psychological disease
  • 8) Patients who receive the continuous whole body dosage (or intravenous internal use) of steroid or other immunosuppressant
  • 9) Unstable angina (within 3 months after onset) , myocardial infarction
  • 10) Difficult-to-control hypertension
  • 11) Difficult-to-control diabetes
  • 12) HBs antigen is positive
  • 13) Judgment to attending physician

研究者

发起方
Hara Hitomi

相似试验

GD therapy for advanced sarcomas | 临床试验